Mometasone and Markers of Airway Inflammation

Creighton University12 enrolled

Overview

A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Asthma

Interventions

PlaceboDRUG

2 puffs, qd

Mometasone FuroateDRUG

400 mcg, qd for 8 weeks

Eligibility

Sex: ALLMin age: 19 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Asthma * non-smoker * FEV1 of at least 60% predicted Exclusion Criteria: * Pregnancy or lactation * Corticosteroid use in past 30 days

Locations (1)

Creighton University Medical Center

Omaha, Nebraska, United States

Outcomes

Primary Outcomes

Exhaled Nitric Oxide

Time frame: 8 weeks

Secondary Outcomes

Airway Reactivity

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.